NCT02675452 2025-07-09AMG 176 First in Human Trial in Participants With Relapsed or Refractory Multiple Myeloma and Participants With Relapsed or Refractory Acute Myeloid LeukemiaAmgenPhase 1 Terminated141 enrolled 46 charts